Jump to content

Meet the Genedata
Expressionist Community

The 2021 Genedata Expressionist User Meeting

During this two-day virtual event attended by more than 150 Genedata users worldwide, scientific experts from leading biopharma companies presented case studies on how Genedata Expressionist is used to streamline and automate complex mass spectrometry (MS)-based data analytical processes.

The overarching theme of the event was the digitalization of biopharma MS data workflows, from early-stage characterization to downstream quality control of biopharmaceuticals. During the meeting, Genedata Expressionist users described how using automated data analysis workflows to perform in-depth characterization of novel biotherapeutics delivers significant increases in project throughput and data quality.

Case studies detailing Multi-attribute Method (MAM) implementations across organizations demonstrated the increasing assimilation of this transformative approach, which delivers increased efficiency and productivity in the development of novel biotherapeutics. Since the emergence of MAM, Genedata has worked with many biopharmaceutical companies in establishing highly automated end-to-end MAM workflows from development to manufacturing.

An entire session was dedicated to the role of MS-based analysis in the development of cell and gene therapies, with Genedata partners showcasing characterization of adeno-associated virus (AAV) capsid proteins and automated analysis of oligonucleotide therapeutics.

A keynote presentation by John Schiel, Ph.D., from NIST drew together all these strands by describing how multi-attribute method approaches are making mass spectrometry a disruptive technology for the characterization of emerging biotherapeutic modalities employed in cell and gene therapies.

“We are delighted about the rapidly growing adoption of Genedata Expressionist for digitalizing complex mass-spectrometry based analytical processes.” said Othmar Pfannes, Ph.D., CEO of Genedata. “We are committed to supporting biopharma in scaling up and automating their R&D workflows. Bringing together industry leaders and learning from them about their daily operational challenges helps us to establish best practices and drive innovation in this highly exciting field.”

Presentations at the 2021 Genedata Expressionist User Meeting

Mass Spectrometry as a Disruptive Technology for Emerging Biotherapeutic Modalities

Validation of LC–MS Multi-Attribute Method Supporting Biopharma Process Characterization

Automation of MS Analytics for Characterization of Biotherapeutics

High-Throughput and Format-Agnostic Mispairing Assay for Multispecific Antibodies Using Intact Mass Spectrometry

Identification and Characterization of Adeno-Associated Virus Capsid Proteins by Mass Spectrometry

Semi-Automated Analysis of Oligonucleotide UV-LCMS Data for Process Development

Software for Quality Control of Oligonucleotides by Mass Spectrometry

High-Throughput Intact Mass Analysis Using Parameterization


Identification of IgG2 Disulfide Isoforms by Non-Reduced Peptide Mapping Workflow

Join us at the Genedata Biopharma Partner Symposium in Basel, Switzerland on March 23–24, 2022


Register Now